$SANA
Sana Biotechnology Inc

2021 Form 10-K Financial Statement

#000156459022010539 Filed on March 16, 2022

View on sec.gov

Income Statement

Concept 2021 2020 Q4 2020
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $50.41M $9.210M $27.77M
YoY Change 81.53% 76.44% 31.11%
% of Gross Profit
Research & Development $248.6M $104.1M $132.9M
YoY Change 87.02% 165.14% 33.49%
% of Gross Profit
Depreciation & Amortization $11.10M $1.750M $5.900M
YoY Change 88.14% 69.9% 227.78%
% of Gross Profit
Operating Expenses $356.9M $113.3M $286.1M
YoY Change 24.73% 154.71% 102.72%
Operating Profit -$356.9M -$286.1M
YoY Change 24.73% 102.72%
Interest Expense $676.0K $130.0K $747.0K
YoY Change -9.5% -80.88% -73.84%
% of Operating Profit
Other Income/Expense, Net $305.0K $30.00K $97.00K
YoY Change 214.43% 50.0% -434.48%
Pretax Income -$355.9M -$113.2M -$285.3M
YoY Change 24.75% 154.94% 106.26%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$355.9M -$113.2M -$285.3M
YoY Change 24.75% 162.88% 118.16%
Net Earnings / Revenue
Basic Earnings Per Share -$2.14 -$21.92
Diluted Earnings Per Share -$2.139M -$615.7K -$1.552M
COMMON SHARES
Basic Shares Outstanding 166.4M 13.01M
Diluted Shares Outstanding 166.4M 13.01M

Balance Sheet

Concept 2021 2020 Q4 2020
SHORT-TERM ASSETS
Cash & Short-Term Investments $551.0M $378.3M $378.3M
YoY Change 45.65% 172.16%
Cash & Equivalents $253.0M $124.8M $124.8M
Short-Term Investments $298.0M $253.5M $253.5M
Other Short-Term Assets $7.105M $6.200M $6.200M
YoY Change 14.6% 16.98%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $558.1M $384.5M $384.5M
YoY Change 45.15% 166.46%
LONG-TERM ASSETS
Property, Plant & Equipment $161.8M $46.78M $109.9M
YoY Change 47.21% 59.74%
Goodwill $140.6M
YoY Change
Intangibles $59.20M
YoY Change
Long-Term Investments $195.9M $33.70M $33.70M
YoY Change 481.25%
Other Assets $13.82M $190.0K $2.300M
YoY Change 500.83% 0.0%
Total Long-Term Assets $571.3M $345.8M $345.8M
YoY Change 65.21% 27.65%
TOTAL ASSETS
Total Short-Term Assets $558.1M $384.5M $384.5M
Total Long-Term Assets $571.3M $345.8M $345.8M
Total Assets $1.129B $730.3M $730.3M
YoY Change 54.65% 75.89%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.219M $2.253M $2.300M
YoY Change -3.52%
Accrued Expenses $38.25M $25.50M $25.50M
YoY Change 49.98% 44.07%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $99.24M $31.45M $31.50M
YoY Change 215.03% 63.21%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $301.7M $540.0K $267.1M
YoY Change 12.94% 120.56%
Total Long-Term Liabilities $301.7M $540.0K $267.1M
YoY Change 12.94% 120.56%
TOTAL LIABILITIES
Total Short-Term Liabilities $99.24M $31.45M $31.50M
Total Long-Term Liabilities $301.7M $540.0K $267.1M
Total Liabilities $400.9M $298.6M $298.6M
YoY Change 34.26% 112.68%
SHAREHOLDERS EQUITY
Retained Earnings -$429.4M
YoY Change
Common Stock $2.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $728.5M -$421.2M $431.7M
YoY Change
Total Liabilities & Shareholders Equity $1.129B $730.3M $730.3M
YoY Change 54.65% 75.89%

Cashflow Statement

Concept 2021 2020 Q4 2020
OPERATING ACTIVITIES
Net Income -$355.9M -$113.2M -$285.3M
YoY Change 24.75% 162.88% 118.16%
Depreciation, Depletion And Amortization $11.10M $1.750M $5.900M
YoY Change 88.14% 69.9% 227.78%
Cash From Operating Activities -$251.1M -$37.56M -$138.0M
YoY Change 81.95% 11.16% 61.35%
INVESTING ACTIVITIES
Capital Expenditures $29.86M -$9.260M $23.87M
YoY Change 25.09% 61.61% -8.62%
Acquisitions
YoY Change
Other Investing Activities $4.574M $22.31M -$228.7M
YoY Change -102.0% -31.37% 270.77%
Cash From Investing Activities -$245.8M $13.04M -$252.6M
YoY Change -2.68% -51.31% 187.46%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 631.8M 110.0K 435.7M
YoY Change 45.0% -98.59% 94.73%
NET CHANGE
Cash From Operating Activities -251.1M -37.56M -138.0M
Cash From Investing Activities -245.8M 13.04M -252.6M
Cash From Financing Activities 631.8M 110.0K 435.7M
Net Change In Cash 134.9M -24.41M 45.14M
YoY Change 198.83% -3113.58% -10.36%
FREE CASH FLOW
Cash From Operating Activities -$251.1M -$37.56M -$138.0M
Capital Expenditures $29.86M -$9.260M $23.87M
Free Cash Flow -$280.9M -$28.30M -$161.9M
YoY Change 73.56% 0.86% 44.98%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.25
CY2021Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.25
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-141152000
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
97000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-355928000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-285305000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-130778000
CY2021Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
195881000
CY2021 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
676000
CY2020 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
747000
CY2019 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
2856000
CY2021 us-gaap Operating Expenses
OperatingExpenses
356909000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-356909000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-286149000
CY2019 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-29000
CY2021 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.14
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-21.92
CY2021 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
166433000
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
13014000
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4903000
CY2019 us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate201602Member
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y8M12D
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y1M6D
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0046
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0036
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0153
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0138
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0151
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0262
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7105000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
558101000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
65464000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
96320000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
8819000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
59195000
CY2021Q4 us-gaap Goodwill
Goodwill
140627000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5000000
CY2021Q4 us-gaap Assets
Assets
1129407000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2219000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
21131000
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
10344000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
9159000
CY2021Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
51382000
CY2021Q4 sana Success Payment Liabilities Current
SuccessPaymentLiabilitiesCurrent
5000000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
99235000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
31451000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
101784000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
68197000
CY2021Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
102361000
CY2020Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
121901000
CY2021Q4 sana Success Payment Liabilities Noncurrent
SuccessPaymentLiabilitiesNoncurrent
97525000
CY2020Q4 sana Success Payment Liabilities Noncurrent
SuccessPaymentLiabilitiesNoncurrent
76494000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
540000
CY2021Q4 us-gaap Liabilities
Liabilities
400905000
CY2021Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
0
CY2020Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
537786000
CY2021Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2021Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2020Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
134113000
CY2020Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
134113000
CY2020Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
852897000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
750000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
707000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
184929000
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
184929000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
16170000
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
16170000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
248626000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
132944000
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
99591000
CY2021 sana Research And Development Related Success Payments And Contingent Consideration
ResearchAndDevelopmentRelatedSuccessPaymentsAndContingentConsideration
57873000
CY2020 sana Research And Development Related Success Payments And Contingent Consideration
ResearchAndDevelopmentRelatedSuccessPaymentsAndContingentConsideration
124935000
CY2019 sana Research And Development Related Success Payments And Contingent Consideration
ResearchAndDevelopmentRelatedSuccessPaymentsAndContingentConsideration
19784000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
50410000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
28270000
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
21777000
CY2020 us-gaap Operating Expenses
OperatingExpenses
286149000
CY2019 us-gaap Operating Expenses
OperatingExpenses
141152000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
305000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-355928000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-285305000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-138325000
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-7547000
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-26.68
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-13188000
CY2019 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
1000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1498000
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000
CY2019 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
26000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-130778000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-142542000
CY2020 us-gaap Temporary Equity Stock Issued During Period Value New Issues
TemporaryEquityStockIssuedDuringPeriodValueNewIssues
435538000
CY2020 sana Stock Issued During Period Value Common Stock In Connection With License Agreement
StockIssuedDuringPeriodValueCommonStockInConnectionWithLicenseAgreement
680000
CY2020 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
1000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5829000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
149000
CY2020 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
4000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-285305000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-421184000
CY2021 sana Temporary Equity Conversion Of Convertible Preferred Stock Into Common Stock Shares
TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStockShares
134113000
CY2021 sana Temporary Equity Conversion Of Convertible Preferred Stock Into Common Stock
TemporaryEquityConversionOfConvertiblePreferredStockIntoCommonStock
852897000
CY2021 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
852897000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3167000
CY2021 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2179000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
22362000
CY2021 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-1396000
CY2019 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-7547000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
1497000
CY2020 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
52793000
CY2019 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
17860000
CY2021 sana Change In Fair Value Of Success Payment Liabilities
ChangeInFairValueOfSuccessPaymentLiabilities
26031000
CY2020 sana Change In Fair Value Of Success Payment Liabilities
ChangeInFairValueOfSuccessPaymentLiabilities
72142000
CY2019 sana Change In Fair Value Of Success Payment Liabilities
ChangeInFairValueOfSuccessPaymentLiabilities
1924000
CY2020 sana Non Cash Expense In Connection With License Agreement And Asset Acquisition
NonCashExpenseInConnectionWithLicenseAgreementAndAssetAcquisition
1530000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-355928000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
728502000
CY2021 us-gaap Profit Loss
ProfitLoss
-355928000
CY2020 us-gaap Profit Loss
ProfitLoss
-285305000
CY2019 us-gaap Profit Loss
ProfitLoss
-130778000
CY2021 us-gaap Depreciation
Depreciation
11070000
CY2020 us-gaap Depreciation
Depreciation
5921000
CY2019 sana Non Cash Expense In Connection With License Agreement And Asset Acquisition
NonCashExpenseInConnectionWithLicenseAgreementAndAssetAcquisition
17685000
CY2021 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
6844000
CY2020 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
4250000
CY2019 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
2095000
CY2021 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
3076000
CY2020 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
1297000
CY2019 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
592000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
861000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1436000
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4300000
CY2021 sana Increase Decrease In Operating Lease Right Of Use Assets And Liabilities
IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities
-5088000
CY2020 sana Increase Decrease In Operating Lease Right Of Use Assets And Liabilities
IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities
-91000
CY2019 sana Increase Decrease In Operating Lease Right Of Use Assets And Liabilities
IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities
-5697000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-266000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1982000
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-421000
CY2021 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
5840000
CY2020 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
5519000
CY2019 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
9536000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-251054000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-137982000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-85518000
CY2021 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
491387000
CY2020 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
387432000
CY2019 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
141519000
CY2021 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
280025000
CY2020 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
158741000
CY2019 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
82977000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
29862000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
23872000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
26124000
CY2019 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
3195000
CY2021 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
4574000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-245798000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-252563000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-87861000
CY2021 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
626405000
CY2020 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
435538000
CY2019 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
223739000
CY2021 sana Proceeds From Employee Stock Purchase Plan And Exercise Of Stock Options Net
ProceedsFromEmployeeStockPurchasePlanAndExerciseOfStockOptionsNet
5346000
CY2020 sana Proceeds From Employee Stock Purchase Plan And Exercise Of Stock Options Net
ProceedsFromEmployeeStockPurchasePlanAndExerciseOfStockOptionsNet
149000
CY2019 sana Proceeds From Employee Stock Purchase Plan And Exercise Of Stock Options Net
ProceedsFromEmployeeStockPurchasePlanAndExerciseOfStockOptionsNet
1000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
631751000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
435687000
CY2020 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
26521000
CY2019 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
48863000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
50361000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
31446000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
223740000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
134899000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
45142000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
261848000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
126949000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
81807000
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
39996000
CY2021 us-gaap Payments For Tenant Improvements
PaymentsForTenantImprovements
5445000
CY2020 us-gaap Payments For Tenant Improvements
PaymentsForTenantImprovements
91000
CY2019 us-gaap Payments For Tenant Improvements
PaymentsForTenantImprovements
5697000
CY2021 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
3015000
CY2020 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
3140000
CY2019 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2495000
CY2019 sana Proceeds From Issuance Of Convertible Preferred Stock For Acquisition
ProceedsFromIssuanceOfConvertiblePreferredStockForAcquisition
135971000
CY2021 us-gaap Nature Of Operations
NatureOfOperations
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. Organization </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Sana Biotechnology, Inc. (the Company or Sana) is a biotechnology company focusing on utilizing engineered cells as medicines. The Company’s operations to date have included identifying and developing potential product candidates, executing preclinical studies, establishing manufacturing capabilities, acquiring technology, organizing and staffing the Company, business planning, establishing the Company’s intellectual property portfolio, raising capital, and providing general and administrative support for these operations.  </p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Reverse stock split </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2021, the Company’s board of directors approved an amendment to the Company’s amended and restated certificate of incorporation to effect a <span style="-sec-ix-hidden:F_000404">1-for-4</span> reverse stock split of shares of the Company’s common and convertible preferred stock, which was effected on January 27, 2021. The par value per share and authorized shares of common and convertible preferred stock were not adjusted as a result of the reverse stock split. All share and per share information included in the accompanying consolidated financial statements has been adjusted to reflect the reverse stock split.</p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Initial public offering </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2021, the Company successfully completed its initial public offering (IPO) of its common stock. In connection with its IPO, the Company issued 27.0 million shares of its common stock, including 3.5 million shares pursuant to the full exercise of the underwriters’ option to purchase additional shares, at a price of $25.00 per share, and received $626.4 million in net proceeds, after deducting underwriting discounts and commissions of $45.2 million and offering expenses of $4.0 million. At the closing of the IPO, 134.1 million shares of convertible preferred stock then outstanding were automatically converted into shares of common stock. The related carrying value of the converted preferred stock of $852.9 million was reclassified to common stock and additional paid in-capital.</p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Need for additional capital </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to a number of risks and uncertainties similar to other biotechnology companies in the development stage, including, but not limited to, those related to the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its product candidates, building out internal and external manufacturing capabilities, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company’s products, the need to protect the Company’s intellectual property and proprietary technology, and the need to attract and retain key scientific and management personnel. If the Company does not successfully commercialize or partner any of its product candidates, it will be unable to generate product revenue or achieve profitability. Until such time as the Company can generate significant revenue from product sales, if ever, it expects to finance its operations with the proceeds from additional equity or debt financings or capital obtained in connection with strategic collaborations or licensing or other arrangements. In the event that additional financing is required, the Company may not be able to raise it on terms acceptable to it or at all.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has incurred operating losses each year since inception and expects such losses to continue for the foreseeable future. As of December 31, 2021, the Company had cash, cash equivalents, and marketable securities of $746.9 million, and an accumulated deficit of $785.4 million, which includes non-cash charges related to the revaluation of the success payment liabilities and contingent consideration of $100.1 million and $102.5 million, respectively.</p>
CY2021 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
In January 2021, the Company’s board of directors approved an amendment to the Company’s amended and restated certificate of incorporation to effect a 1-for-4 reverse stock split of shares of the Company’s common and convertible preferred stock, which was effected on January 27, 2021.
CY2021Q4 us-gaap Investments And Cash
InvestmentsAndCash
746900000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-785400000
CY2021Q4 sana Success Payment Liabilities
SuccessPaymentLiabilities
100100000
CY2021Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
102500000
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates. The most significant estimates in the Company’s consolidated financial statements relate to success payment liabilities, contingent consideration, business combinations, accrued expenses, operating lease right of use assets and liabilities, and the valuation of stock options. </p>
CY2021 us-gaap Concentration Risk Credit Risk Financial Instruments Off Balance Sheet Risk
ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk
The Company has no off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts, or other hedging arrangements.
CY2019Q3 us-gaap Stock Issued During Period Shares Acquisitions
StockIssuedDuringPeriodSharesAcquisitions
12100000
CY2020Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
11582000
CY2021Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
4429000
CY2021 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
46775000
CY2021 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
0
CY2021 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021 us-gaap Depreciation
Depreciation
11100000
CY2020 us-gaap Depreciation
Depreciation
5900000
CY2019 us-gaap Depreciation
Depreciation
1800000
CY2021Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
13814000
CY2021 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
17337000
CY2021Q4 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2019Q1 sana Business Combination Consideration Transferred Milestone Payment
BusinessCombinationConsiderationTransferredMilestonePayment
38800000
CY2021 us-gaap Restricted Cash And Cash Equivalents Noncurrent Nature Of Restriction Description
RestrictedCashAndCashEquivalentsNoncurrentNatureOfRestrictionDescription
standby letters of credit
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
8800000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2100000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
8819000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2143000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
84238000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
54512000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
18774000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7737000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
65464000
CY2020Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
2441000
CY2021Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
2888000
CY2020Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
1997000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
21131000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
16020000
CY2021Q4 sana Accrued Research And Development Expense Services Current
AccruedResearchAndDevelopmentExpenseServicesCurrent
3419000
CY2020Q4 sana Accrued Research And Development Expense Services Current
AccruedResearchAndDevelopmentExpenseServicesCurrent
1197000
CY2021Q4 sana Accrued Property And Equipment Current
AccruedPropertyAndEquipmentCurrent
2566000
CY2020Q4 sana Accrued Property And Equipment Current
AccruedPropertyAndEquipmentCurrent
2892000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1971000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1717000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2388000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3660000
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
10344000
CY2020Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
9466000
CY2021 sana Operating Lease Expiration Beginning Month And Year
OperatingLeaseExpirationBeginningMonthAndYear
2024-04
CY2021 sana Operating Lease Expiration Ending Month And Year
OperatingLeaseExpirationEndingMonthAndYear
2031-11
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
16425000
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
10757000
CY2019 us-gaap Operating Lease Cost
OperatingLeaseCost
4898000
CY2021 us-gaap Short Term Lease Cost
ShortTermLeaseCost
512000
CY2020 us-gaap Short Term Lease Cost
ShortTermLeaseCost
1886000
CY2019 us-gaap Short Term Lease Cost
ShortTermLeaseCost
3710000
CY2021 us-gaap Variable Lease Cost
VariableLeaseCost
5230000
CY2020 us-gaap Variable Lease Cost
VariableLeaseCost
3081000
CY2019 us-gaap Variable Lease Cost
VariableLeaseCost
1494000
CY2021 us-gaap Lease Cost
LeaseCost
22167000
CY2020 us-gaap Lease Cost
LeaseCost
15724000
CY2019 us-gaap Lease Cost
LeaseCost
10102000
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y10M17D
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0915
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
19954000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
21511000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
20601000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
20449000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
17701000
CY2021Q4 sana Lessee Operating Lease Liability Payments Due Year Five And Thereafter
LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter
80913000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
181129000
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
66291000
CY2021Q4 sana Lessee Operating Lease Liability Tenant Improvement Allowance
LesseeOperatingLeaseLiabilityTenantImprovementAllowance
3895000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
110943000
CY2021Q1 sana Preferred And Common Shares Authorized
PreferredAndCommonSharesAuthorized
800000000.0
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.96
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
141718000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3215000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.61
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
41382000
CY2020Q4 sana Capital Stock Shares Authorized
CapitalStockSharesAuthorized
707000000.0
CY2020Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
537800000
CY2020Q4 sana Capital Stock Par Or Stated Value Per Share
CapitalStockParOrStatedValuePerShare
0.0001
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
750000000.0
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000.0
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
184900000
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
16200000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
22362000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5828000
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1497000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
15677000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.52
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
4165000
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
22.57
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1586000
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.00
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
919000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
6.88
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.70
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.70
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.70
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
14.22
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.52
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.92
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
29880000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
605000
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
25000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
101900000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
12400000
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0275
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0209
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0306
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.2406
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.1518
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.1632
CY2021 sana Effective Income Tax Rate Reconciliation Success Payment Liabilities
EffectiveIncomeTaxRateReconciliationSuccessPaymentLiabilities
-0.0140
CY2020 sana Effective Income Tax Rate Reconciliation Success Payment Liabilities
EffectiveIncomeTaxRateReconciliationSuccessPaymentLiabilities
-0.0458
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Contingencies
EffectiveIncomeTaxRateReconciliationTaxContingencies
-0.0188
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Contingencies
EffectiveIncomeTaxRateReconciliationTaxContingencies
-0.0389
CY2019 us-gaap Effective Income Tax Rate Reconciliation Tax Contingencies
EffectiveIncomeTaxRateReconciliationTaxContingencies
-0.0271
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.0258
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.0188
CY2019 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.0193
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.0101
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0132
CY2019 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0150
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0000
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0000
CY2019 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0546
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
114368000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
58527000
CY2021Q4 sana Deferred Tax Assets Lease Liabilities
DeferredTaxAssetsLeaseLiabilities
25754000
CY2020Q4 sana Deferred Tax Assets Lease Liabilities
DeferredTaxAssetsLeaseLiabilities
16971000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
24008000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
11908000
CY2021Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
5986000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
4401000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
3643000
CY2021Q4 sana Deferred Tax Assets Success Payment Liabilities
DeferredTaxAssetsSuccessPaymentLiabilities
3290000
CY2020Q4 sana Deferred Tax Assets Success Payment Liabilities
DeferredTaxAssetsSuccessPaymentLiabilities
2785000
CY2021Q4 sana Deferred Tax Assets Stock Based Compensation
DeferredTaxAssetsStockBasedCompensation
1854000
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
25000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
179661000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
93859000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
156622000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
70989000
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
23039000
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
22870000
CY2021Q4 sana Deferred Tax Liabilities Right Of Use Assets
DeferredTaxLiabilitiesRightOfUseAssets
21940000
CY2020Q4 sana Deferred Tax Liabilities Right Of Use Assets
DeferredTaxLiabilitiesRightOfUseAssets
14577000
CY2021Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
1050000
CY2020Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
935000
CY2020Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
6870000
CY2020Q4 sana Deferred Tax Liabilities Stock Based Compensation
DeferredTaxLiabilitiesStockBasedCompensation
488000
CY2021Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
49000
CY2021Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
23039000
CY2020Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
22870000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-355928000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-285305000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-130778000
CY2021 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
166433000
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
13014000
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4903000
CY2021 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.14
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-21.92
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-26.68
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
21843000
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
160195000
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
127924000
CY2021 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0

Files In Submission

Name View Source Status
0001564590-22-010539-index-headers.html Edgar Link pending
0001564590-22-010539-index.html Edgar Link pending
0001564590-22-010539.txt Edgar Link pending
0001564590-22-010539-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g4ow3etw3vd5000001.jpg Edgar Link pending
g4ow3etw3vd5000002.jpg Edgar Link pending
g4ow3etw3vd5000003.jpg Edgar Link pending
g4ow3etw3vd5000004.jpg Edgar Link pending
g4ow3etw3vd5000005.jpg Edgar Link pending
g4ow3etw3vd5000006.jpg Edgar Link pending
g4ow3etw3vd5000007.jpg Edgar Link pending
g4ow3etw3vd5000008.jpg Edgar Link pending
g4ow3etw3vd5000009.jpg Edgar Link pending
g4ow3etw3vd5000010.jpg Edgar Link pending
g4ow3etw3vd5000011.jpg Edgar Link pending
g4ow3etw3vd5000012.jpg Edgar Link pending
g4ow3etw3vd5000013.jpg Edgar Link pending
g4ow3etw3vd5000014.jpg Edgar Link pending
g4ow3etw3vd5000015.jpg Edgar Link pending
g4ow3etw3vd5000016.jpg Edgar Link pending
g4ow3etw3vd5000017.jpg Edgar Link pending
g4ow3etw3vd5000018.jpg Edgar Link pending
g4ow3etw3vd5000019.jpg Edgar Link pending
g4ow3etw3vd5000020.jpg Edgar Link pending
g4ow3etw3vd5000021.jpg Edgar Link pending
g4ow3etw3vd5000022.jpg Edgar Link pending
g4ow3etw3vd5000023.jpg Edgar Link pending
g4ow3etw3vd5000024.jpg Edgar Link pending
g4ow3etw3vd5000025.jpg Edgar Link pending
g4ow3etw3vd5000026.jpg Edgar Link pending
g4ow3etw3vd5000027.jpg Edgar Link pending
g4ow3etw3vd5000028.jpg Edgar Link pending
g4ow3etw3vd5000029.jpg Edgar Link pending
g4ow3etw3vd5000030.jpg Edgar Link pending
g4ow3etw3vd5000031.jpg Edgar Link pending
g4ow3etw3vd5000032.jpg Edgar Link pending
g4ow3etw3vd5000033.jpg Edgar Link pending
g4ow3etw3vd5000034.jpg Edgar Link pending
g4ow3etw3vd5000035.jpg Edgar Link pending
g4ow3etw3vd5000036.jpg Edgar Link pending
g4ow3etw3vd5000037.jpg Edgar Link pending
g4ow3etw3vd5000038.jpg Edgar Link pending
g4ow3etw3vd5000039.jpg Edgar Link pending
g4ow3etw3vd5000040.jpg Edgar Link pending
g4ow3etw3vd5000041.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
sana-10k_20211231.htm Edgar Link pending
sana-10k_20211231_htm.xml Edgar Link completed
sana-20211231.xsd Edgar Link pending
sana-20211231_cal.xml Edgar Link unprocessable
sana-20211231_def.xml Edgar Link unprocessable
sana-20211231_lab.xml Edgar Link unprocessable
sana-20211231_pre.xml Edgar Link unprocessable
sana-ex1011_634.htm Edgar Link pending
sana-ex1015d_1048.htm Edgar Link pending
sana-ex1015e_1049.htm Edgar Link pending
sana-ex1025_1266.htm Edgar Link pending
sana-ex103d_15.htm Edgar Link pending
sana-ex104b_14.htm Edgar Link pending
sana-ex104d_13.htm Edgar Link pending
sana-ex231_10.htm Edgar Link pending
sana-ex311_7.htm Edgar Link pending
sana-ex312_9.htm Edgar Link pending
sana-ex321_8.htm Edgar Link pending
sana-ex322_6.htm Edgar Link pending
Show.js Edgar Link pending